

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
10 February 2005 (10.02.2005)

PCT

(10) International Publication Number
WO 2005/012220 A2

(51) International Patent Classification⁷: **C07C 59/00**

(21) International Application Number:
PCT/US2004/024308

(22) International Filing Date: 27 July 2004 (27.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/490,588 28 July 2003 (28.07.2003) US

(71) Applicant (for all designated States except US):
SMITHKLINE BEECHAM CORPORATION
[US/US]; One Franklin Plaza, Philadelphia, PA 19101
(US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BRITTON**,
Jonathan, E. [US/US]; GlaxoSmithKline, Five Moore
Drive, P.O. Box 13398, Research Triangle Park, NC
27709 (US). **FANG, Jing** [CN/US]; GlaxoSmithKline,
Five Moore Drive, P.O. Box 13398, Research Trian-
gle Park, NC 27709 (US). **HEYER, Dennis** [US/US];
GlaxoSmithKline, Five Moore Drive, P.O. Box 13398,
Research Triangle Park, NC 27709 (US). **MILLER**,
Aaron, Bayne [US/US]; GlaxoSmithKline, Five Moore
Drive, P.O. Box 13398, Research Triangle Park, NC 27709
(US). **NAVAS, Frank, III** [US/US]; GlaxoSmithKline,
Five Moore Drive, P.O. Box 13398, Research Triangle
Park, NC 27709 (US). **SMALLEY, Terrence, Lee, Jr.**
[US/US]; GlaxoSmithKline, Five Moore Drive, P.O.
Box 13398, Research Triangle Park, NC 27709 (US).
ZUERCHER, William, J. [US/US]; GlaxoSmithKline,

Five Moore Drive, P.O. Box 13398, Research Triangle
Park, NC 27709 (US). **KALAMREDDY, Subba, Reddy**
[IN/US]; GlaxoSmithKline, Five Moore Drive, P.O. Box
13398, Research Triangle Park, NC 27709 (US).

(74) Agents: **LEVY, David, J.** et al.; GlaxoSmithKline, Five
Moore Drive, P.O. Box 13398, Research Triangle Park, NC
27709 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: **CHEMICAL COMPOUNDS**

(57) Abstract: The present invention relates to novel compounds with a variety of therapeutic uses, more particularly novel substi-
tuted cyclic alkylidene compounds that are particularly useful for selective estrogen receptor modulation.

WO 2005/012220 A2